Drug susceptibility of mycobacterium tuberculosis Beijing genotype and association with MDR TB

Emerging Infectious Diseases

Volumn 18, Issue 4, 2012, Pages 660-663

  de Steenwinkel, Jurriaan E M ^a   ten Kate, Marian T ^a   de Knegt, Gerjo J ^a   Kremer, Kristin ^b,c   Aarnoutse, Rob E ^d   Boeree, Martin J ^d   Verbrugh, Henri A ^a   van Soolingen, Dick ^b,d   Bakker Woudenberg, Irma A J M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ISONIAZID; MOXIFLOXACIN; RIFAMPICIN;

ARTICLE; CONTROLLED STUDY; GENE; GENOTYPE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MUT GENE; MUTATION RATE; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

AMIKACIN; ANTITUBERCULAR AGENTS; AZA COMPOUNDS; BACTERIAL PROTEINS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GENOTYPE; ISONIAZID; MICROBIAL SENSITIVITY TESTS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; QUINOLINES; RIFAMPIN; STATISTICS, NONPARAMETRIC; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84858640651     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1804.110912     Document Type: Article

References (15)

1. World Health Organization. Multidrug and extensively drugresistant TB (M/XDR-TB): 2010 global report on surveillance and response: 2010 global report on surveillance and response. 2010 Mar [cited 2011 Jun 11]. http://www.who.int/tb/publications/2010/978924599191/en/index.html
2. European Concerted Action on New Generation Genetic Markers and Techniques for the Epidemiology and Control of Tuberculosis. Beijing/W genotype Mycobacterium tuberculosis and drug resistance. Emerg Infect Dis. 2006;12:736-43. http://dx.doi.org/10.3201/eid1205.050400
3. Parwati I, van Crevel R, van Soolingen D. Possible underlying mechanisms for successful emergence of the Mycobacterium tuberculosis Beijing genotype strains. Lancet Infect Dis. 2010;10:103-11. http://dx.doi.org/10.1016/S1473-3099(09)70330-5
4. Buu TN, Huyen MN, Lan NN, Quy HT, Hen NV, Zignol M, et al. Mycobacterium tuberculosis genotype and case notification rates, rural Vietnam, 2003-2006. Emerg Infect Dis. 2009;15:1570-7.
5. Buu TN, Huyen MN, Lan NT, Quy HT, Hen NV, Zignol M, et al. The Beijing genotype is associated with young age and multidrugresistant tuberculosis in rural Vietnam. Int J Tuberc Lung Dis. 2009;13:900-6.
6. van der Spuy GD, Kremer K, Ndabambi SL, Beyers N, Dunbar R, Marais BJ, et al. Changing Mycobacterium tuberculosis population highlights clade-specific pathogenic characteristics. Tuberculosis (Edinb). 2009;89:120-5. http://dx.doi.org/10.1016/j.tube.2008.09.003
7. Anh DD, Borgdorff MW, Van LN, Lan NT, van Gorkom T, Kremer K, et al. Mycobacterium tuberculosis Beijing genotype emerging in Vietnam. Emerg Infect Dis. 2000;6:302-5. http://dx.doi.org/10.3201/eid0603.000312
8. Cowley D, Govender D, February B, Wolfe M, Steyn L, Evans J, et al. Recent and rapid emergence of W-Beijing strains of Mycobacterium tuberculosis in Cape Town, South Africa. Clin Infect Dis. 2008;47:1252-9. http://dx.doi.org/10.1086/592575
9. Lan NT, Lien HT, Tung le B, Borgdorff MW, Kremer K, van Soolingen D. Mycobacterium tuberculosis Beijing genotype and risk for treatment failure and relapse, Vietnam. Emerg Infect Dis. 2003;9:1633-5.
10. Hershberg R, Lipatov M, Small PM, Sheffer H, Niemann S, Homolka S, et al. High functional diversity in Mycobacterium tuberculosis driven by genetic drift and human demography. PLoS Biol. 2008;6:e311. http://dx.doi.org/10.1371/journal.pbio.0060311
11. National Committee for Clinical Laboratory Standards. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes; approved standard-second edition. CLSI document M24-A; 2011 [cited 2011 Feb 11]. http://www.clsi.org/source/orders/free/m24-a2.pdf
12. Gumbo T. New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamics science and population pharmacokinetic variability. Antimicrob Agents Chemother. 2010;54:1484-91. http://dx.doi.org/10.1128/AAC.01474-09
13. Ebrahimi-Rad M, Bifani P, Martin C, Kremer K, Samper S, Rauzier J, et al. Mutations in putative mutator genes of Mycobacterium tuberculosis strains of the W-Beijing family. Emerg Infect Dis. 2003;9:838-45.
14. Werngren J, Hoffner SE. Drug-susceptible Mycobacterium tuberculosis Beijing genotype does not develop mutation-conferred resistance to rifampin at an elevated rate. J Clin Microbiol. 2003;41:1520-4. http://dx.doi.org/10.1128/JCM.41.4.1520-1524.2003
15. de Steenwinkel JE, de Knegt GJ, ten Kate MT, van Belkum A, Verbrugh HA, Kremer K, et al. Time-kill kinetics of anti-tuberculosis drugs, and emergence of resistance, in relation to metabolic activity of Mycobacterium tuberculosis. J Antimicrob Chemother. 2010;65:2582-9. http://dx.doi.org/10.1093/jac/dkq374